- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Prospective, Multicentre
- Study aim: To evaluate the clinical outcome, viral clearance, and incidence of resistance-associated mutations that emerged during therapy in a cohort of 245 ICPs with COVID-19 treated with casirivimab/imdevimab, sotrovimab, and tixagevimab/cilgavimab
- Number of participants enrolled: 245
- Study enrolling from to
- Study includes follow-up for 3 months
Study Data
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
External Links
Other information
Funders:
- Roche
- Horizon Europe
- ZorgOnderzoek Nederland
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to